Abbott presented new clinical data highlighting strong outcomes for its technologies targeting heart rhythm disorders at the Heart Rhythm Society 2026 conference. The results covered multiple trials across its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios, including treatments for atrial fibrillation.

Six-month data from the FlexPulse study showed high success rates, with 87% of patients free from arrhythmias and a strong safety profile, while additional studies demonstrated promising results for Abbott’s investigational pacing and defibrillation devices.

The company said the findings reinforce the effectiveness and safety of its technologies and support ongoing innovation in treating complex cardiac conditions through more advanced and personalized therapies.
PRNewswire